Log in
Many clinically-useful natural products fall into the class of polyketides. From 1993, research led by Professors Leadlay (Biochemistry) and Staunton (Chemistry) on polyketide biosynthesis pathways led to the foundation of the spin-out company Biotica Technology Ltd in 1996. Between 2008 and 2013 the company provided continuous employment for on average 15-20 highly-skilled scientists, and attracted additional investments of £4.43M. Its follow-on company Isomerase Therapeutics Ltd, founded by ex-Biotica researchers with Leadlay's support in 2013, has acquired compounds, strains and IP from Biotica. Using the methods developed in the University by Leadlay and Staunton, Biotica developed a HepC antiviral therapy, sold in 2013 to NeuroVive Pharmaceuticals AB and currently entering pre-clinical toxicology tests. Biotica have also licensed their technology to a number of companies globally, including GSK and Amyris.
Research on the anatomy, physiology and palaeoecology of pterosaurs by the Palaeobiology Group at Portsmouth University has had a wide and acknowledged impact, underpinning the creation and production of block-buster and pioneering television and film productions worldwide. The impact of this work is recognised by Sir David Attenborough, and by the producers of such TV successes as Walking With Dinosaurs and Flying Monsters 3D. These award-winning productions, highlighting our work, have reached a global audience and supported the generation of millions of pounds by the UK TV and film industry. Whilst the income generated is highly significant, perhaps their greatest impact lies in fostering a positive view of science, particularly in young audiences, by bringing cutting-edge evolutionary science direct to the World's film and TV screens.
Research into electrochemical biosensors conducted at the University of Cambridge between 1998 and 2002 led to the development of the WaveSense™ line of diabetes products by start-up, AgaMatrix. By 2012 AgaMatrix had sold 3M glucose meters & 3B biosensor test strips worldwide across 20,000+ retail locations including Boots UK, and since 2010 also globally in partnership with Sanofi. [text removed for publication] AgaMatrix UK continues to grow its business with compound annual growth rates for revenue in excess of 100%. Agamatrix UK now supplies over one million glucose test strips per month to the NHS. Agamatrix has developed >10 FDA-cleared products since 2008, including the first FDA approved smartphone linked diagnostic device.
£80m has been saved since 2008 by London Underground (LU) and yet more by bridge owners in the UK as a direct result of using the Arching Action (AA) enhancements in strength predicted by our research. The associated disruption would have resulted in enormous congestion, losses economically of £ billions and negative social impact. Multi-million $ savings have also accrued in North America from the use of corrosion free deck bridges, which have minimum maintenance, as has our innovative flexible concrete arch (patented 2004) which has been used for over 40 FlexiArch bridges (£15m in contracts) since 2008.
Radiation sources and amplifiers, in the spectral region from microwave to terahertz, are extensively used in UK industry and public sectors such as security, defence, health and the environment. Companies, including e2v Technologies plc. (e2v) and TMD Technologies Ltd. (TMD), have developed and sold new radiation products based on post-1996 research undertaken at the University of Strathclyde. Their devices accessed new frequency ranges with considerable increases in power and bandwidth. The designs were transferred to industry, where devices have been constructed, jobs created, policy changed and considerable investments made. These sources have had extensive beneficial impact through applications in defence, surveillance, materials processing, health sciences and environmental monitoring.
Economic impact is claimed through the growth of the biopharmaceutical spin-out company Q Chip Ltd. During the REF period, this has created 19 new jobs, £7.5M investment, a new Dutch subsidiary (Q Chip BV), and staged-payment, six figure contract sales to four major international pharmaceutical companies.
Q Chip has generated over £928K in contract sales from the pharmaceutical industry from 2008-2012, with further sales of over £1M projected in 2013-14.
Originally established by Professor David Barrow in 2003 from his micro technology research, Q Chip has developed new processes and miniaturised equipment to encapsulate materials, including drugs, within uniform polymeric microspheres as injectable therapeutics.
Work at Birmingham by Peter Knowles and Fred Manby on improving the efficiency of calculating integrals for so-called ab initio calculations, widely used in computational chemistry, has led to a novel, fast algorithm for the accurate calculation of molecular energies and structures. It contains a level of theory, known as MP2, widely used in modelling by industry (pharmaceutical and chemical) as well as in academia. The new local approximation of the method, DF-LMP2, was developed at Birmingham and implemented in the MOLPRO package that has been sold worldwide, generating economic impact. A major attraction of the package is that MOLPRO can do a range of calculations efficiently, MP2 being one of them.
Research at University of Cambridge Department of Engineering (DoEng) has created a new fundamental understanding of the static, dynamic and blast performance of lattice sandwich structures (a repeating pattern of metal struts between two sheets of metal). Ship builders in the Netherlands and the USA have built over 19 ships worth approximately GB200M using this technology since 1/1/2008 with many more planned. These ships are:
This research into rich donors in the UK has impacted on the policies of both governmental and non-governmental bodies. Government policy shapes and incentivises philanthropic behaviour (e.g. through tax incentives), whilst charity sector bodies influence philanthropic norms and build trust: both have used this research to guide their policy and practice. Examples include the influence of the research on the content of the UK Government's Giving White Paper (2011); the decision to abandon the proposed cap on charity tax relief (2012 Budget); and the work of bodies who promote fundraising and philanthropy, for example, the Institute of Fundraising, Philanthropy UK and Charities Aid Foundation (CAF).
The work of Colledge and colleagues between 2000 and 2007 has identified and characterised a molecule which is an important regulator of fertility: the neuropeptide kisspeptin.
The identification of its role in fertility has led to kisspeptin and its analogues being tested in clinical trials to make IVF treatment safer (Phase II: one trial), and as therapeutic agents for reproductive system conditions such as delayed puberty, menopause and absence of menstruation (Phase I: four trials). In April 2013, 11 months after the start of the Phase II IVF study, a healthy baby has been born to a participant treated with kisspeptin. Patients enrolled in these fertility trials have testified to the improvement in quality of life which the hope of being able to conceive that this alternative to conventional IVF has brought them.